Venetoclax Resistance: Mechanisms and Treatment Options

preview_player
Показать описание

In this webcast from the 'First- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy' symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Matthew S. Davids discusses venetoclax resistance in CLL patients.

© 2019 Imedex, an HMP Company
  1. HMP Education
  2. Imedex
  3. CME
  4. Continuing Medical Education
  5. Education
  6. Accreditation
Рекомендации по теме
Venetoclax Resistance: Mechanisms 0:20:43

Venetoclax Resistance: Mechanisms and Treatment Options

Understanding the mechanisms 0:01:33

Understanding the mechanisms of venetoclax and ibrutinib resistance

Resistance Mechanisms in 0:04:15

Resistance Mechanisms in AML and Treatment Decisions

Venetoclax resistance and 0:01:42

Venetoclax resistance and alternative treatments in CLL

Resisitance mechanisms to 0:03:31

Resisitance mechanisms to venetoclax in patients with progressive CLL

Mechanisms of resistance 0:03:42

Mechanisms of resistance to venetoclax in AML and methods being explored to overcome these

Resistance mechanisms of 0:02:43

Resistance mechanisms of current treatments in CLL

Mechanisms of resistance 0:02:43

Mechanisms of resistance to CAR-T therapy in lymphoma & potential strategies to overcome these

Ibrutinib resistance-mechanisms and 0:29:14

Ibrutinib resistance-mechanisms and options in CLL

Venetoclax-based strategies in 0:19:46

Venetoclax-based strategies in AML

BTK and BCL2 0:03:12

BTK and BCL2 inhibitor resistance in CLL: session highlights

Update on venetoclax 0:21:50

Update on venetoclax for CLL: How low can you go (MRD)?

Resistance to Venetoclax 0:03:46

Resistance to Venetoclax in CLL

Immunotherapy resistance mechanisms 0:02:05

Immunotherapy resistance mechanisms and predicting NMIBC patient immune responses.

Clonal evolution and 0:03:37

Clonal evolution and resistance mechanisms to BCL-2 receptor inhibition

AML Treatment Challenges 0:18:29

AML Treatment Challenges Who, When, and How

What predicts disease 0:05:15

What predicts disease progression on venetoclax?

An insight into 0:03:12

An insight into resistance mechanisms of CLL cells to CAR-T therapy

Overcoming venetoclax resistance 0:03:16

Overcoming venetoclax resistance in AML with MCL1 inhibition

Venetoclax in Chronic 0:05:51

Venetoclax in Chronic Lymphocytic Leukemia

Resistance mechanisms in 0:02:13

Resistance mechanisms in CLL and the importance of genomic re-testing

Acute Myeloid Leukemia 0:38:47

Acute Myeloid Leukemia

Mechanisms of resistance 0:03:58

Mechanisms of resistance in multiple myeloma treatments

Understanding and overcoming 0:01:51

Understanding and overcoming resistance mechanisms to novel agents used in CLL